Molin L, Schmid F, Bolla K
Surv Immunol Res. 1985;4 Suppl 1:76-80. doi: 10.1007/BF02919060.
Eight patients suffering from active rheumatoid arthritis were treated with thymopentin, 50 mg, administered as fractionated intravenous infusion over 10 min 3 times weekly for 3-20 weeks. Seven patients experienced clear-cut amelioration of symptoms and signs after just 2-4 weeks of treatment, and this improvement lasted for 6-8 weeks after thymopentin had been discontinued. Comparable positive results were observed in 2 patients who later continued thymopentin therapy by subcutaneous administration. Several subcutaneous dose regimens were tried; the optimal response appears to be achieved with 100-150 mg three times weekly and 150-200 mg twice a week, respectively. Because the subcutaneous therapeutic approach is more attractive to the patient-and also more practical for the physician-it should be investigated further.
八名患有活动性类风湿性关节炎的患者接受了胸腺五肽治疗，剂量为50毫克，分三次静脉输注，每次10分钟，每周三次，持续3至20周。七名患者在治疗仅2至4周后症状和体征就明显改善，且在停用胸腺五肽后这种改善持续了6至8周。另外两名患者后来通过皮下给药继续接受胸腺五肽治疗，也观察到了类似的阳性结果。尝试了几种皮下给药方案；每周三次100 - 150毫克和每周两次150 - 200毫克的剂量似乎能达到最佳反应。由于皮下治疗方法对患者更具吸引力，对医生来说也更实用，因此应进一步研究。
